Sci. Signal., 6 November 2012
Science Signaling Podcast: 6 November 2012
Michael A. Frohman1 and Annalisa M. VanHook2
1 Department of Pharmacological Sciences, Center for Developmental Genetics, and Graduate Program in Molecular and Cellular Pharmacology, Stony Brook University, Stony Brook, NY 11794–5140, USA.
Abstract: This is an interview with Michael Frohman, senior author of a Research Article that appears in this issue of Science Signaling. Frohmans group has investigated the role of the enzyme phospholipase D1 (PLD1) in the tumor microenvironment. PLD1 produces the lipid phosphatidic acid, which acts as a second messenger in many signaling pathways and promotes proliferation, survival, and metastasis of cancer cells. When tumor cells were implanted into mice lacking PLD1, the resulting tumors were smaller and less vascularized than those that developed in wild-type mice and produced fewer lung metastases. Treating wild-type mice with a PLD1 inhibitor also inhibited tumor growth and metastasis, suggesting that inhibiting the activity of PLD1 might be a useful approach for treating human cancers.
Citation: M. A. Frohman, A. M. VanHook, Science Signaling Podcast: 6 November 2012. Sci. Signal. 5, pc25 (2012).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882